276 related articles for article (PubMed ID: 9467548)
1. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition.
Touati G; Prieur AM; Ruiz JC; Noel M; Czernichow P
J Clin Endocrinol Metab; 1998 Feb; 83(2):403-9. PubMed ID: 9467548
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone treatment of short stature and metabolic dysfunction in juvenile chronic arthritis.
Simon D; Touati G; Prieur AM; Ruiz JC; Czernichow P
Acta Paediatr Suppl; 1999 Feb; 88(428):100-5. PubMed ID: 10102064
[TBL] [Abstract][Full Text] [Related]
3. Treatment of juvenile rheumatoid arthritis with growth hormone.
Simon D; Prieur A; Czernichow P
Horm Res; 2000; 53 Suppl 1():82-6. PubMed ID: 10895048
[TBL] [Abstract][Full Text] [Related]
4. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study.
Simon D; Prieur AM; Quartier P; Charles Ruiz J; Czernichow P
J Clin Endocrinol Metab; 2007 Jul; 92(7):2567-73. PubMed ID: 17488793
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study.
Simon D; Alberti C; Alison M; Le Henaff L; Chevenne D; Boizeau P; Canal A; Ollivier G; Decostre V; Jacqz-Aigrain E; Carel JC; Czernichow P; Hogrel JY
J Clin Endocrinol Metab; 2013 Jul; 98(7):2746-54. PubMed ID: 23626006
[TBL] [Abstract][Full Text] [Related]
6. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone (GH)-binding protein in prepubertal short children born small for gestational age: effects of growth hormone treatment. Swedish Study Group for Growth Hormone Treatment.
Boguszewski M; Bjarnason R; Rosberg S; Carlsson LM; Albertsson-Wikland K
J Clin Endocrinol Metab; 1997 Apr; 82(4):1014-9. PubMed ID: 9100566
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
[TBL] [Abstract][Full Text] [Related]
9. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone.
Bechtold S; Ripperger P; Mühlbayer D; Truckenbrodt H; Häfner R; Butenandt O; Schwarz HP
J Clin Endocrinol Metab; 2001 Dec; 86(12):5737-44. PubMed ID: 11739431
[TBL] [Abstract][Full Text] [Related]
10. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
[TBL] [Abstract][Full Text] [Related]
14. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
[TBL] [Abstract][Full Text] [Related]
15. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
[TBL] [Abstract][Full Text] [Related]
16. Body composition, fasting leptin, and sex steroid administration determine GH sensitivity in peripubertal short children.
Coutant R; Boux de Casson F; Rouleau S; Douay O; Mathieu E; Audran M; Limal JM
J Clin Endocrinol Metab; 2001 Dec; 86(12):5805-12. PubMed ID: 11739442
[TBL] [Abstract][Full Text] [Related]
17. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial.
Willemsen RH; Arends NJ; Bakker-van Waarde WM; Jansen M; van Mil EG; Mulder J; Odink RJ; Reeser M; Rongen-Westerlaken C; Stokvis-Brantsma WH; Waelkens JJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2007 Oct; 67(4):485-92. PubMed ID: 17561977
[TBL] [Abstract][Full Text] [Related]
19. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
[TBL] [Abstract][Full Text] [Related]
20. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.
Carroll PV; Drake WM; Maher KT; Metcalfe K; Shaw NJ; Dunger DB; Cheetham TD; Camacho-Hübner C; Savage MO; Monson JP
J Clin Endocrinol Metab; 2004 Aug; 89(8):3890-5. PubMed ID: 15292323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
